linjc16/ctgov huggingface dataset:
Prevalence and Sequelae of Computer Vision Syndrome in Egyptian Universities

Study Overview
=================
Brief Summary
-----------------
CVS-F4 questionnaire will be used as an instrument to survey CVS prevalence and severity among medical students

Detailed Description
-----------------
CVS-F4 (30 questions) will be an online survey via the SurveyMonkey Company. We will collect the responses and analyze the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. The questionnaire includes questions regarding potential ocular, extra-ocular, musclo-skeletal and neuro-psychatric complains caused by CVS. Complete statistical analysis of the survey data will be done using univariate and multivariate logistic and linear regression analysis. The CVS diagnosis will be based on the 5 diagnostic criteria (5DC) to create a new short self-assessment questionnaire for accurate prevalence of CVS.

Official Title
-----------------
A Novel Smart Self-assessment Questionnaire for Accurate Diagnosis and Prevalence of Computer Vision Syndrome: a Multicenter Cross-sectional Study

Conditions
-----------------
Computer Vision Syndrome

Intervention / Treatment
-----------------
* Behavioral: CVS Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: university students university staff members Exclusion Criteria: ocular surgery amblyopia anisometropia strabismus systemic disease

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control Group<br>The participants will respond to CVS-F4 questionnaire online via SurveyMonkey to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. This group will contains participants with no CVS complains. | Behavioral: CVS Group<br>* CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants suffering from CVS | will be reported in form of percentage (%) of students with CVS | 3 months | 
| Rate of CVS symptoms-attacks | The results will be presented as annual percentage | 3 months |
Cough Determinants in Mechanically Ventilated Patients

Study Overview
=================
Brief Summary
-----------------
In our knowledge there is only few data about the cough determinants in mechanically ventilated patients. However some failure of extubation is due to inefficiency cough. In order to determine some determinants of cough, the investigators propose to evaluate systematically different physiological parameters before and after extubation.

Detailed Description
-----------------
In order to evaluate, and identify the cough determinants, the investigators propose a physiological evaluation for each patients who were intubated and mechanically ventilated during at least 72 hours. Indeed inefficacy of cough after extubation is one of the main reason of extubation failure. However there is no any mean to evaluate it simply now.

Official Title
-----------------
Cough Determinants in Mechanically Ventilated Patients: a Physiological Study

Conditions
-----------------
Mechanical Ventilation

Intervention / Treatment
-----------------
* Other: Functional respiratory evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients mechanically ventilated since 72h Age > 18 years Hospitalized in Intensive care Unit In weaning phase - with the classically criteria to be extubated Patients who passed the weaning test (T tube test or other) Exclusion Criteria: Hemodynamic instability Absence of consent No cooperation of the patient Hemodynamic instability pH < 7,30 Severe hypoxemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Cough Determinants<br> | Other: Functional respiratory evaluation<br>* Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)<br>* Other names: Pulmonary Function test;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interest of systematically cough evaluation before extubation | All the patients enrolled have a physiological evaluation before and after extubation. After extubation the evaluation will be done respectively at D0, D1, D3 and D5. The first endpoint is the success of extubation which is evaluated à D2. | 2 days after extubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between success of extubation and respiratory parameters |  | 2 days after extubation |
Safety of Thoracoscopy in Patients With High Risk

Study Overview
=================
Brief Summary
-----------------
Medical thoracoscopy can be performed for diagnostic as well as therapeutic purposes. Thoracoscopy in the diagnosis of pleural diseases is highly sensitive for detecting pleural neoplasia with negative pleural fluid cytology and in the diagnosis of tuberculosis. The indication of thoracoscopy in patients with pleural effusion has been optimized. In some studies medical thoracoscopy has been claimed a useful diagnostic tool with a very low rate of complications. However the investigators do not know its safety on high risk patients. Because many patients having suspected malignancy have bed conditions due to other health problems such as coronary heart diseases, COPD, arrythmia, hypoxemia. In this study the investigators aimed to test the safety of medical thoracoscopy in the patients with high risk for complications.

Official Title
-----------------
Safety of Thoracoscopy in Patients With High Risk

Conditions
-----------------
Pleural Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with exudative pleural effusion Exclusion Criteria: Patients without pleural effusion

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with high risk<br> | |
| Patients in normal conditions<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | All participants will have been followed for side effects of medical thoracoscopy. All side effects established in the special forms designed for this study. Side effects measured and recorded according to each characteristic such as pain, air leakege, pneumothorax, empyema, local infection, haemorragy etc. | 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thoracoscopy, pleural diseases, complications, safety
Hemodynamics During the Soccer Championship 2012

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine in soccer fans whether and to which extend positive or negative emotions during the European soccer Championship affects Central Hemodynamics, Arterial Stiffness, Heartrate and Endothelial Dysfunktion.

Official Title
-----------------
Central Hemodynamics, Arterial Stiffness, Heartrate and Endothelial Dysfunktion During the European Soccer Championship 2012

Conditions
-----------------
Severe Cardiomyopathy, Angina, Unstable, Myocardial Infarction, Angina, Stable

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Best fit: cardiomyopathy severe myocardial disease leading to heart failure Angina, stable for at least 7 days Myocardial infarction during 4 weeks before inclusion, actually stable condition Angina, Stable, CCS II-IV Exclusion Criteria: not interested in soccer championship age <18y dementia atrial tachycardia drug/alcohol abuse chronic kidney disease, stage 5 pulmonary/tricuspid valve insufficiency/stenoses non compliant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and efficacy of glucocorticosteroid for treatment of drug-induced liver injury.

Official Title
-----------------
Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial

Conditions
-----------------
Drug-induced Liver Injury

Intervention / Treatment
-----------------
* Drug: Glucocorticoids+hepatoprotectant
* Drug: hepatoprotectant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of DILI RUCAM score≥6 and with liver histology Meet any of the following conditions: TBIL ≥ 10 fold ULN ; TBIL ≥ 5 fold ULN and serum AST or ALT ≥ 20 fold ULN Exclusion Criteria: An chronic onset (≥6 months) Other liver diseases, such as autoimmune liver diseases, viral hepatitis, etc with contraindications of glucocorticoid

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: glucocorticoid+hepatoprotectant group<br>glucocorticoid 0.4mg/kg/d+hepatoprotectant for 7d | Drug: Glucocorticoids+hepatoprotectant<br>* Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.<br>* Other names: methylprednisolone;|
| Active Comparator: hepatoprotectant group<br>hepatoprotectant for 7d | Drug: hepatoprotectant<br>* Participants received hepatoprotectants (i.v.gtt.) for 7 days.<br>* Other names: Polyene Phosphatidyl choline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients that AST or ALT decline 25% at day 4 | AST or ALT decline 25% at day 4 | Change from Baseline ALT and AST at day4 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients that AST or ALT decline 50% at day 8 | AST or ALT decline 25% at day 8 | Change from Baseline ALT and AST at day8 | 
| the time needed when TBIL decline 50% | TBIL decline 50%; time | up to 2 weeks | 
| incidence of side effects | infection，uncontrolled hypertension or hyperglycemia | up to 2 years | 
| relapse rate in 12 months after drug withdrawal | relapse rate | 12 months after drug withdrawal | 
| mortality in 12 months after drug withdrawal | mortality | 12 months after drug withdrawal | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glucocorticosteroid
High-intensity Interval Training Enhances Mobilization/Functionality of Endothelial Progenitor Cells and Depressed Shedding of Vascular Endothelial Cells Undergoing Hypoxia

Study Overview
=================
Brief Summary
-----------------
Exercise training improves endothelium-dependent vasodilation, whereas hypoxic stress causes vascular endothelial dysfunction. Monocyte- derived endothelial progenitor cells (Mon-EPCs) contribute to vascular repair process by differentiating into endothelial cells. This study investigates how high-intensity interval (HIT) and moderate intensity-continuous (MCT) exercise training affect circulating Mon-EPC levels and EPC functionality under hypoxic condition. Sixty healthy sedentary males were randomized to engage either HIT (3-minute intervals at 40% and 80%VO2max , n=20) or MCT (sustained 60%VO2max , n=20) for 30 minutes/day, 5 days/week for 6 weeks, or to a control group that did not received exercise intervention (n=20). Mon-EPC characteristics and EPC functionality under hypoxic exercise (HE, 100W under 12%O 2 ) were determined before and after various interventions.

Conditions
-----------------
Hypoxia

Intervention / Treatment
-----------------
* Behavioral: HIT
* Behavioral: MCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sedentary life Age 20 28 Exclusion Criteria: Smokers Users of medication/vitamins Any cardiopulmonary/hematological risk Regular exercise habits at least 1 year Exposed to high altitudes (>3000 m) for at least 1 year

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 28 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High intensity-interval (HIT)<br> | Behavioral: HIT<br>* 3-minute intervals at 40% and 80%VO 2max<br>|
| Experimental: moderate intensity-continuous (MCT)<br> | Behavioral: MCT<br>* sustained 60%VO 2max<br>|
| No Intervention: control (CTL)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circulating progenitor cells conten | by flow cytometry before and after rehabilitation circulating progenitor cells conten before and after hypoxic exercise test | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiopulmonary fitness |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endothelial progenitor cell, hemodynamic, Exercise, HIIT
Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine

Study Overview
=================
Brief Summary
-----------------
Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus genetic reassortment vaccine.

Conditions
-----------------
Randomized, Double-blind, Placebo Control Design

Intervention / Treatment
-----------------
* Biological: trivalent rotavirus genetic reassortment vaccine
* Biological: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 to 13 weeks aged healthy baby; Guardian volunteer to participate in the study and sign informed consent; have use thermometer as required and the ability to fill in the diary table; Subjects guardian can abide by the requirements of clinical research scheme; The past has not been vaccinated rotavirus vaccine; Normal term eutocia, birth weight up to standard; Axillary temperature is 37.0 ℃ or less. Exclusion Criteria: With allergy, convulsion, epilepsy, encephalopathy and spirit history or the family history; Be allergy to any ingredients in the vaccine; Known immunology function damage or low person; Immunosuppressant therapy Accepter; Suffering from congenital malformation and developmental disorder; Known or suspected also suffer from diseases including: digestive system disease, respiratory system disease, acute infection, mother or I have HIV infection, cardiovascular diseases, malignant tumor during treatment, skin disease; Inoculation other vaccine within 7 days.

Ages Eligible for Study
-----------------
Minimum Age: 6 Weeks
Maximum Age: 13 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: trivalent rotavirus genetic reassortment vaccine<br>2ml of rotavirus genetic reassortment vaccine by mouth every month for three month | Biological: trivalent rotavirus genetic reassortment vaccine<br> <br> |
| Placebo Comparator: Placebo<br>2ml of placebo by mouth every month for three month | Biological: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody titer differences in serum |  | 4 weeks after full vaccination | 
| Incidence differences of rotavirus diarrhea |  | 2 years after full vaccination. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rotavirus, trivalent genetic reassortment vaccine, Phase three clinical trials
Laparoscopic Gastrectomy for Advanced Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
Although laparoscopic gastrectomy (LG) is widely used for the treatment of early gastric cancer, there have been few reports of the efficacy of LAG in the management of advanced gastric cancer(AGC). The aim of this study is to evaluate the surgical outcomes and oncologic safety of laparoscopic gastrectomy for AGC.

Detailed Description
-----------------
Prospective phase II clinical trial to evaluate technical and oncological safety of LG for AGC LG procedure for AGC: D2 lymphadenectomy Total omentectomy for tumor with serosa exposure under laparoscopic exploration Primary end point: 3 year disease free survival secondary end point: postoperative outcomes, morbidity and mortality, 3,5 and 7 year overall survival, Quality of life, recurrence pattern Study duration: 7 years(enrollment: 4year, follow-up: 3year)

Official Title
-----------------
Laparoscopic Gastrectomy for Advanced Gastric Cancer

Conditions
-----------------
Advanced Gastric Cancer, Laparoscopic Gastrectomy

Intervention / Treatment
-----------------
* Procedure: Laparoscopic gastrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20-80 informed consent no other malignancies cT2N0-cT3N2 according to JGCA 2nd edition ASA score<3 Exclusion Criteria: distant metastasis(P1 or M1) under laparoscopic exploration Conglomerated N2 early gastric cancer in permanent pathologic report

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Laparoscopic gastrectomy<br>Laparoscopic gastrectomy procedure: D2 lymphadenectomy & total omentectomy in case of tumor with serosa exposure under laparoscopic exploration | Procedure: Laparoscopic gastrectomy<br>* Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3 year recurrence free survival | Evaluation of recurrence after regular 3 months follow-up using tumor marker, chest x-ray, endoscopy and computed tomograhy. | Postoperative 3 year |